Krebs Biochemicals and Industries share price
NSE: KREBSBIOBSE: 524518Pharmaceuticals & BiotechnologySmall Cap
Formerly Krebs Biochemicals
Last close ₹51.85down ₹5.63 (9.79%)BSE ₹52.99
Share price at the NSE close on 23 Oct 2026. Previous close ₹57.48.
52-week range of traded prices to 23 Oct 2026
₹38.33Low, 30 Mar 2026₹76.85High, 5 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 29 Oct 2026 to consider: financial results and other business matters.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹112 Cr2,740th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Net worth zero or below
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 6 Aug 2026
- −14.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 27,82269.3% delivered
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 6 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹6.98 Crup 2.56%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹2.48 CrQuarter to Mar 2026: −₹2.34 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −35.6%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 10 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2019, the company's revenue for that year, ₹48 Cr, differs from its quarters added, ₹40 Cr. From the year to Mar 2021, the company's revenue for that year, ₹54 Cr, differs from its quarters added, ₹41 Cr. From the year to Mar 2022, the company's revenue for that year, ₹53 Cr, differs from its quarters added, ₹58 Cr.
| ₹ crore | Sep 2024Filed 11 Nov | Dec 2024Filed 4 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 7 Aug | Sep 2025Filed 4 Nov | Dec 2025Filed 9 Feb | Mar 2026Filed 21 May | Jun 2026Filed 6 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.9 | 11.5 | 6.1 | 5.5 | 4.2 | 7.3 | 6.8 | 7.0 |
| Net profit | −5.8 | −7.7 | −8.3 | −5.3 | −6.1 | −3.1 | −2.3 | −2.5 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | −44.8% | −67.5% | −135.5% | −97.1% | −147.4% | −43.0% | −34.4% | −35.6% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacturing of Drugs, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −40.1% | – | – | 0.0% |
| 3 years | −11.1% | – | – | 0.0% |
| 5 years | −14.3% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Krebs Biochemicals and Industries in market cap.
Krebs Biochemicals and Industries is not on the chart: it has no P/E or return on equity today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Godavari DrugsGODAVARI | 122 | 29.3 | 1.6 | 18.5 | +4.8% | +9.7% | 7.0% | 4.9% | 0.00% |
| Himalaya Nutravedics IndiaHNIL | 121 | – | – | – | – | – | – | – | 0.00% |
 Parnax LabPARNAXLAB | 119 | 13.3 | 1.2 | 7.9 | +31.9% | −17.3% | 10.0% | 9.3% | 0.00% |
 BALAXI PHARMACEUTICALSBALAXI | 115 | 47.6 | 0.5 | 17.3 | −5.9% | −87.2% | 1.0% | 2.1% | 0.00% |
 Makers LaboratoriesMAKERSL | 110 | 32.3 | 1.5 | 6.1 | +17.6% | −61.6% | 4.8% | 11.1% | 0.00% |
 Tyche IndustriesTYCHE | 107 | 24.0 | 0.8 | – | −21.0% | −63.5% | 3.2% | −2.5% | 3.36% |
 Alpa LaboratoriesALPA | 104 | – | 0.6 | – | +0.5% | – | – | −1.8% | 0.00% |
 Pharmaids PharmaceuticalsPHARMAID | 102 | – | 2.1 | – | +18.5% | – | −8.5% | −15.8% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
Aug 2026
Krebs Biochemicals and Industries share price by year
Each calendar year to 2025.Krebs Biochemicals and Industries share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 69.04 | −25.8% | 104.94 | 64.54 |
| 2024 | 92.99 | +18.7% | 125.30 | 61.45 |
| 2023 | 78.35 | −28.5% | 117.70 | 52.05 |
| 2022 | 109.65 | −45.5% | 213.05 | 99.35 |
| 2021 | 201.35 | +44.8% | 201.35 | 85.95 |
| 2020 | 139.05 | +78.6% | 141.60 | 64.10 |
| 2019 | 77.85 | −31.7% | 128.55 | 67.15 |
| 2018 | 113.95 | −17.5% | 204.15 | 90.05 |
| 2017 | 138.05 | +74.7% | 138.05 | 76.95 |
| 2016 | 79.00 | – | 102.40 | 77.00 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2016 is from its first session, 27 Oct 2016.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 58.50 | 58.50 | 50.71 | 51.85 | 52.97 | 27,822 | 69.3% |
| 22 Oct 2026 | 57.00 | 58.98 | 56.31 | 57.48 | 57.69 | 3,570 | 26.7% |
| 21 Oct 2026 | 57.16 | 59.00 | 55.58 | 56.06 | 57.49 | 8,422 | 56.3% |
| 19 Oct 2026 | 60.80 | 60.80 | 57.10 | 57.88 | 58.30 | 4,543 | 57.2% |
| 16 Oct 2026 | 59.60 | 60.99 | 58.21 | 60.19 | 59.46 | 8,945 | 65.9% |
| 15 Oct 2026 | 60.38 | 61.70 | 59.13 | 60.82 | 60.38 | 17,674 | 53.0% |
| 14 Oct 2026 | 57.00 | 63.95 | 55.43 | 60.41 | 60.52 | 47,475 | 45.0% |
| 13 Oct 2026 | 55.81 | 59.80 | 55.75 | 57.29 | 57.06 | 8,398 | 35.0% |
| 12 Oct 2026 | 55.21 | 57.70 | 54.51 | 56.64 | 55.89 | 14,475 | 75.4% |
| 9 Oct 2026 | 57.50 | 59.49 | 55.11 | 56.00 | 56.75 | 29,630 | 66.9% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Rights issue history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 31 Jan 2019 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
Each event is noted and not adjusted for.
Company details
- Legal name
- Krebs Biochemicals and Industries Limited
- NSE symbol
- KREBSBIO
- BSE code
- 524518
- ISIN
- INE268B01013
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jan 1996 on NSE, May 2000 on BSE
- Face value
- ₹10
- CIN
- L24110AP1991PLC103912
- Corporate identity number, the registrar of companies' code for it